Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, and its news flow centers on the development of two key product candidates: DA-1726 for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241) for MASH and type 2 diabetes. Company announcements frequently highlight clinical trial progress, new data readouts, and regulatory or listing updates that are relevant to investors and healthcare professionals following obesity and liver disease therapeutics.
News about DA-1726 includes Phase 1 multiple ascending dose results in obese but otherwise healthy adults, pharmacokinetic data supporting once-weekly subcutaneous dosing, and extended 8-week dosing cohorts at 48 mg. MetaVia has reported statistically significant weight loss, reductions in waist circumference, improvements in fasted glucose, and reductions in liver stiffness as measured by vibration-controlled transient elastography (VCTE), along with a favorable safety and tolerability profile. The company also releases updates on scientific presentations at meetings such as ObesityWeek, where DA-1726 data are shared with the medical community.
For vanoglipel (DA-1241), MetaVia’s news coverage includes Phase 2a trial results in presumed MASH patients, showing clinically meaningful reductions in glycated hemoglobin (HbA1c), improvements in liver inflammation and fibrosis markers, better liver steatosis and stiffness measures, and favorable shifts in plasma lipidomic profiles. The company announces poster presentations at major conferences such as the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, where detailed hepatic and metabolic data are presented.
In addition to clinical data, MetaVia issues news on corporate and capital market developments, including its 1-for-11 reverse stock split and communications regarding compliance with Nasdaq’s minimum bid price requirement. Readers of the MTVA news page can expect updates on trial milestones, conference presentations, research collaborations, and listing status, providing a consolidated view of MetaVia’s progress in cardiometabolic and liver disease drug development.
MetaVia (NASDAQ: MTVA) has announced a $10.0 million private placement priced at-the-market under Nasdaq rules. The offering includes 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 with an exercise price of $0.001. The clinical-stage biotech company plans to use the proceeds for working capital and continued clinical development of DA-1726 for obesity treatment. The private placement, exclusively placed by Ladenburg Thalmann & Co. Inc., is expected to close around May 12, 2025. The securities are being offered to institutional accredited investors under Section 4(a)(2) of the Securities Act and will require registration with the SEC for resale.
MetaVia (Nasdaq: MTVA) announced that data from its Phase 2a clinical trial of DA-1241, a novel GPR119 agonist, will be presented as a late-breaking poster at the EASL Congress 2025 in Amsterdam (May 7-10, 2025). The presentation will focus on the drug's hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) from a 16-week randomized placebo-controlled trial.
The presentation titled 'DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients' will be delivered by Dr. Rohit Loomba from the University of California, San Diego. The poster will be available on MetaVia's website following the presentation.
MetaVia (Nasdaq: MTVA) reported additional positive top-line results from Phase 1 Multiple Ascending Dose (MAD) study of DA-1726, its novel 3:1 ratio GLP-1 and glucagon dual receptor agonist for obesity treatment. The 28-day, 36-subject trial demonstrated:
- Dose-dependent body weight reduction across 8-32mg range, with maximum -6.3% and mean -4.3% weight loss at 32mg dose by Day 26
- No significant cardiovascular effects observed, with most treatment groups showing slight decrease in heart rate
- Strong safety profile with only mild gastrointestinal adverse events in 4/6 subjects at 32mg dose, resolving within 24 hours
The drug showed promising results compared to current GLP-1 agonists, with early satiety observed in 83% of subjects at 32mg dose. Additional cohorts are being added to determine maximum tolerated dose, and a Phase 1 Part 3 study is planned to evaluate DA-1726 in patients who discontinued Wegovy®.
MetaVia (NASDAQ: MTVA) announced positive results from its 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726, a novel dual receptor agonist for obesity treatment. The 32mg dose cohort demonstrated a maximum weight loss of 6.3% and mean weight loss of 4.3% at Day 26 (p=0.0005), with no titration required.
Key findings include:
- Maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches at Day 33
- Maximum lowering of fasted glucose of -18 mg/dL and mean lowering of -5.3 mg/dL
- 25% of subjects experienced mostly mild gastrointestinal adverse events
- No treatment-related discontinuations or serious adverse events
The company plans to conduct Phase 1 Part 3 study investigating DA-1726 on Wegovy early drop-out patients, aiming to demonstrate superior tolerability and safety. Additional cohorts will be added to determine maximum tolerated dose.
MetaVia (NASDAQ: MTVA) announced its 2024 financial results and corporate updates. The company reported significant progress in its cardiometabolic drug development programs:
Key highlights include positive Phase 2a trial results for DA-1241 in MASH treatment, showing ALT level reduction and improved HbA1C levels. The company expects top-line data from Phase 1 MAD Part 2 trial of DA-1726 for obesity treatment in April 2025.
Financial results show:
- R&D expenses increased to $21.6M from $9.2M in 2023
- Net loss of $27.6M ($3.56 per share) compared to $12.5M in 2023
- Cash position of $16.0M, expected to fund operations into Q3 2025
MetaVia (NASDAQ: MTVA) announced it will hold an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference to discuss previously announced positive top-line 16-week results from their Phase 2a clinical trial. The trial evaluated DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
The conference is being held from January 9-11 at the Chateaux Deer Valley in Park City, Utah. MetaVia's management and clinical team will be available in the Exhibit Hall to discuss the trial results, and the presentation will be accessible on the company's website.
MetaVia (Nasdaq: MTVA) announced its participation as a Sponsor and Exhibitor at the 9th Annual MASH-TAG 2025 Conference, scheduled for January 9-11 at the Chateaux Deer Valley in Park City, Utah. This announcement follows the company's recent disclosure of positive top-line 16-week results from their Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The company's management and clinical team will be present at the conference's Exhibit Hall to discuss the trial results.
MetaVia (NASDAQ: MTVA) announced positive top-line results from its Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial demonstrated that DA-1241 (100mg) achieved statistically significant reduction in ALT levels at weeks 4 and 8, with near-significant reduction at week 16.
Key findings include statistically significant improvements in CAP Score and HbA1c levels at Week 16. The drug showed strong safety profile with mostly mild adverse events and no drug-related serious adverse events. The study involved 109 randomized patients across two parts: testing DA-1241 alone and in combination with sitagliptin.
MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.
The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.
FAQ
What is the current stock price of MetaVia (MTVA)?
What is the market cap of MetaVia (MTVA)?
